Yuan Zhao-Di, Zhu Wei-Ning, Liu Ke-Zhi, Huang Zhan-Peng, Han Yan-Chuang
Department of Cardiology, Center for Translational Medicine, Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Grade 19, Sun Yat-sen University Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Stem Cells Int. 2020 Oct 20;2020:8890917. doi: 10.1155/2020/8890917. eCollection 2020.
Although innovative technologies for somatic cell reprogramming and transdifferentiation provide new strategies for the research of translational medicine, including disease modeling, drug screening, artificial organ development, and cell therapy, recipient safety remains a concern due to the use of exogenous transcription factors during induction. To resolve this problem, new induction approaches containing clinically applicable small molecules have been explored. Small molecule epigenetic modulators such as DNA methylation writer inhibitors, histone methylation writer inhibitors, histone acylation reader inhibitors, and histone acetylation eraser inhibitors could overcome epigenetic barriers during cell fate conversion. In the past few years, significant progress has been made in reprogramming and transdifferentiation of somatic cells with small molecule approaches. In the present review, we systematically discuss recent achievements of pure chemical reprogramming and transdifferentiation.
尽管体细胞重编程和转分化的创新技术为转化医学研究提供了新策略,包括疾病建模、药物筛选、人工器官开发和细胞治疗,但由于诱导过程中使用外源性转录因子,受体安全性仍是一个问题。为了解决这个问题,人们探索了包含临床适用小分子的新诱导方法。小分子表观遗传调节剂,如DNA甲基化写入抑制剂、组蛋白甲基化写入抑制剂、组蛋白酰化读取抑制剂和组蛋白乙酰化擦除抑制剂,可以克服细胞命运转换过程中的表观遗传障碍。在过去几年中,小分子方法在体细胞重编程和转分化方面取得了重大进展。在本综述中,我们系统地讨论了纯化学重编程和转分化的最新成果。